PTO/S8/26 (09-04)

Approved for use through 97/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCULATION.

Discussion of the Page Work of the Page Work

I EKWIIN	REJECTION OVER A "PRIOR" PATENT	CV01185K1X US
In re Application of:	Chackalamannil, et al.	
Application No.:	10/705,282	
Filed:	November 10, 2003	
For:	METHODS OF USE OF THROMBIN RECEPTOR ANTAGONISTS	
The owner. SCHERING CORPORATION of 100% percent interest in the instant application hereby disclaims except as provided below, the terminal part of the statutory torm of any patient granted on the instant application which would extend beyon the expiration date of the full statutory term prior patents. 6, 605.38,427 as the term of said prior patent is defined and state of the sta		
is found invalid is statutorily dis has all claims of is reissued; or	by a court of competent jurisdiction; scalamed in whole or terminally disclaimed under 37 CFR 1.321; canceled by a reexamination certificate; er terminated prior to the expiration of its full statutory term as presently shortened by	y any terminal disclaimer.
Check either box 1	or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.		
belief are believed i made are punishab	sciare that all statements made herein of my own knowledge are true and that all to be true; and further that these statements were made with the knowledge that te by fine or imprisonment, or both, under Section 1001 of Title 18 of the United learning the validity of the application or any patient issued thereon.	willful false statements and the like so
2. X The under	signed is an attorney or agent of record. Reg. No. 43.041  MMV - MMMV - Signature	May 12, 2008 Date
	Gerard E. Reinhardt	
Typed or printed name		
		(908) 298-2960
		Telephone Number
X Terminal	disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
Form PTO/SB/96 ma	7 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner), ay be used for making this certification. See MPEP § 324.	
This collection of inform to process) an applicati	nation is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the on. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is	he public which is to file (and by the USPTO s estimated to take 12 minutes to complete,

This collection of information is required by 37 CFR 1.31. The information is required to obtain or retain a benefit by the public which is to life (and by the USFTO is process) an application. Confidentiality is governed by 38 U.S. 0.12 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 cannot be complete. Indicating the complete of the process of the confidence of the USFTO. Time will vary depending upon the individual case. Any commodition on the annual of the rey var equire to complete his from another supplements for excluding this burden, should be sent to the Chef Information CFR of the CFR of the